Pharmaceuticals

Oral Biologics & Biosimilars Market 2026 witnessing rapid scale-up with high CAGR of 21.6% through 2030

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Oral Biologics & Biosimilars Market During The Forecast Period 2026–2030?

The oral biologics & biosimilars market size has seen substantial growth in recent years. It is anticipated to expand from $9.37 billion in 2025 to $11.28 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 20.3%. This historical growth can be linked to the restricted availability of oral biologics, the elevated cost of biologic therapies, a strong reliance on injectable formulations, the increasing prevalence of chronic diseases, and the expanding networks of hospitals and retail pharmacies.

The oral biologics & biosimilars market is projected for substantial growth in the upcoming years. It is expected to reach $24.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 21.6%. This expansion during the forecast period is driven by the advancement of biosimilars and combination therapies, the broadening of oral biologics pipelines, an increasing patient preference for oral medications, the rising adoption of digital adherence tools, and growing government support and reimbursement policies. Key trends for the forecast period include the increasing use of oral biologics and biosimilars for chronic diseases, growth in targeted therapies for conditions such as diabetes, arthritis, and cancer, the accelerating development of monoclonal antibody-based oral treatments, the expansion of distribution channels across hospitals, retail, and online pharmacies, and a strong focus on patient adherence and personalized treatment plans.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

Which Economic Or Industry Drivers Are Impacting The Oral Biologics & Biosimilars Market?

The escalating incidence of chronic illnesses is anticipated to stimulate the expansion of the oral biologics and biosimilar market in the coming years. Chronic diseases are defined as persistent health conditions that typically advance slowly, encompassing ailments such as diabetes, cardiovascular diseases, and various respiratory disorders. The growth in chronic diseases is largely propelled by sedentary lifestyles, as sustained physical inactivity heightens the risk of obesity, heart conditions, type 2 diabetes, and certain types of cancer. Oral biologics and biosimilars facilitate this by providing more accessible, economical, and convenient treatment options for patients managing long-term conditions. For illustration, in January 2023, information from the Centers for Disease Control and Prevention (CDC), a U.S. federal agency, showed that in 2023, 76.4% of U.S. adults (approximately 194 million people) reported having at least one chronic condition, with reported rates of 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the increasing prevalence of chronic diseases is a primary driver for the growth of the oral biologics and biosimilar market.

What Market Segments Are Evaluated Within The Oral Biologics & Biosimilars Market?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Immunostimulants, GPCR Modulators, Other Therapies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

3) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

4) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

What Industry Trends Are Redefining The Oral Biologics & Biosimilars Market?

Major companies in the oral biologics & biosimilars market are concentrating on developing innovative solutions, such as tailored smart capsule development services, to enhance the oral delivery of biologics, improve bioavailability, and enable patient-friendly administration when compared to traditional injectable formulations. Smart capsules are engineered with advanced coatings, controlled-release matrices, or protective excipients that shield biologics from degradation in the gastrointestinal tract and optimize absorption in targeted intestinal regions, presenting a non-invasive alternative to injections and improving patient adherence. For instance, in December 2024, Lonza Group AG, a Switzerland-based contract development and manufacturing organization (CDMO), launched a customized service for smart capsule development, specifically supporting oral biologics development. This service includes customized formulation design, protective excipient selection, and capsule engineering to ensure biologic stability and targeted release; it functions by boosting the oral bioavailability of sensitive biomolecules while maintaining therapeutic efficacy. Unique aspects encompass end-to-end support from concept to preclinical testing, compatibility with multiple biologic modalities (proteins, peptides, nucleic acids), and scalable manufacturing solutions. Applications span the oral delivery of monoclonal antibodies, therapeutic peptides, and vaccines, with benefits including improved patient convenience, reduced reliance on injections, enhanced compliance, and accelerated development timelines for oral biologic therapies.

Who Are The Top Market Participants Influencing The Oral Biologics & Biosimilars Market?

Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

Read the full oral biologics & biosimilars market report here:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

What Are The Top-Performing Regions Within The Oral Biologics & Biosimilars Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oral Biologics & Biosimilars Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6830&type=smp

Browse Through More Reports Similar to the Global Oral Biologics & Biosimilars Market 2026, By The Business Research Company

Dermatology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795